You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1189 Elucidating the effects of chemotherapy and immune checkpoint blockade on the activity of tarlatamab, a DLL3-targeting bispecific T cell engager molecule, in small cell lung cancer preclinical models

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immuno-Conjugates and Chimeric Molecules
1189 Elucidating the effects of chemotherapy and immune checkpoint blockade on the activity of tarlatamab, a DLL3-targeting bispecific T cell engager molecule, in small cell lung cancer preclinical models

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023262026
Dec 2023116019
Jan 20244105
Feb 202458016
Mar 20248408
Apr 20243407
May 202464016
Jun 202471014
Jul 2024116010
Aug 20244808
Sep 2024116018
Oct 202466022
Nov 202474019
Dec 202466017
Jan 202587030
Feb 202536014
Mar 20250015
Apr 20250017
May 20250011
Jun 20252011
Total13410303